FDA Extends Review of Tinlarebant Drug

The agency pushed its decision on Belite Bio's Stargardt disease treatment from February to May 2026.

Updated on Nov. 20, 2026 in Biotech

FDA Extends Review of Tinlarebant Drug

The FDA extended its review of Belite Bio's new drug application for tinlarebant by three months. The expected action date moved from February 12, 2026 to May 12, 2026.

Why it matters

The extension gives the agency additional time to review the new drug application for tinlarebant, an oral candidate for Stargardt disease type 1. If approved, it would be the first drug for that condition in the United States.

A phase 3 trial of tinlarebant found a 35.7% reduction in lesion growth compared with placebo. The FDA's review now runs to May 12, 2026, and the agency's final decision remains unresolved.

The players

Belite Bio

Belite Bio is a biopharmaceutical company developing tinlarebant for inherited retinal diseases.

U.S. Food and Drug Administration

The FDA is the federal agency responsible for reviewing and approving new drugs in the United States.

The details

Tinlarebant is an oral small-molecule drug that reduces vitamin A-related toxins linked to retinal disease. Belite Bio holds FDA breakthrough therapy, fast track, and rare pediatric disease designations for the treatment of Stargardt disease type 1.

Timeline

  1. December 2025: Tinlarebant passed its phase 3 trial.

  2. February 12, 2026: Original FDA action date.

  3. May 12, 2026: Extended FDA action date.

The Tech Race

Tinlarebant is among the oral drugs targeting vitamin A metabolism in the eye, a pathway that has drawn development efforts for Stargardt disease. Ocugen's gene therapy for the same condition has data expected in the first half of 2027, which would compete for the same patients.

If approved, tinlarebant would give patients with Stargardt disease type 1 an oral option, the first such drug available in the U.S. Patients would need to watch for the FDA's May 12, 2026 decision as the next checkpoint.

The takeaway

Regulatory timelines can shift even after positive phase 3 results, so patients and caregivers should track official FDA updates for tinlarebant's status.

What happens next

The FDA is scheduled to issue its decision on tinlarebant by May 12, 2026.

Further reading

Explore more biotech news for context on drug development pipelines.